Alnylam Pharmaceuticals, Inc.
ALNYHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Alnylam Pharmaceuticals, Inc. focuses on Biotechnology services and products. Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. At a $39.45B market cap, Alnylam Pharmaceuticals, Inc. ranks as a large-cap company within healthcare. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1.
Market Cap
$39.45B
Beta
0.30
P/E (TTM)
74.06
P/E (Fwd)
21.15
EPS (TTM)
$3.99
EPS (Fwd)
$13.97
ROE
90.4%
ROA
10.1%
Cash
$3.01B
Total Debt
$2.97B
Free CF
$204.7M
52W Change
3.5%
Annual Financials
Cash vs Debt
With $3.01B in cash and $2.97B in debt, ALNY maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow comes in at $204.7M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 90.4% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 10.1% further supports the picture of efficient asset utilization. Revenue has grown from $1.04B (2022) to $3.71B (2025), reflecting a 258% increase over the period.
With a beta below 0.7, Alnylam Pharmaceuticals, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. At over 50x earnings, ALNY carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Alnylam Pharmaceuticals, Inc. and its sector.